Page 3 - MRS Abstracts March 2023

All standards will be presented, but for the purposes of this abstract key results for discussion follow.
Results:
1. 100% of corticosteroids were tapered as the patient responded to treatment.
2. In presence of muscle inflammation 94% were treated with DMARDs.
3. In presence of active skin disease, 96% received treatment with csDMARD, IVIG or rituximab.
4. Risk of cancer was considered, and appropriate screening carried out in 94%
5. In presence of active muscle disease, 44% of patients received an exercise program led and monitored by therapists.
6. In 11% of patients’ psychological well-being and health was formally considered.
Conclusions:
This multicentre service evaluation offers a degree of generalisability to reflect typical strengths and weaknesses encountered in delivering rheumatology services.
There is strong concordance in diagnostic and pharmacological domains (1-4). However greater variability is encountered with multidisciplinary psychosocial domains involving access to therapy services and psychological support (5-6). This aligns with findings from the BSR workforce report
Tools such as the 36 Item Short Form Survey, highlighted in BSR IIM recommendations, may offer a validated method for physicians to formally target psychosocial domains in management of Idiopathic Inflammatory Myopathies.
Further extension is currently underway to increase representation of patients with IIM and management in the East Midlands.
Key points:
This multicentre East Midlands service evaluation of patients with myositis using a retrospective clinic letter audit against British Society of Rheumatology Idiopathic Inflammatory Myopathy standards, reflects typical strengths and weaknesses in delivering rheumatology services. Areas for improvement are particularly within psychosocial domains, with strengths in diagnostic and pharmacological care.
References:
Audit and Guidelines Working Group, British Society for Rheumatology guideline on management of paediatric, adolescent and adult patients with idiopathic inflammatory myopathy, Rheumatology, Volume 61, Issue 5, May 2022, Pages 1760–1768,